v3.25.1
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenue    
Research and collaboration revenue $ 858 $ 0
Operating Expenses:    
Research and development 10,146 9,740
General and administrative 3,812 3,135
Total operating expenses 13,958 12,875
Loss from operations (13,100) (12,875)
Other income, net:    
Interest income 588 395
Other income (expense) 79 28
Total other income, net 667 423
Net loss attributable to common stockholders (12,433) (12,452)
Comprehensive loss $ (12,433) $ (12,452)
Net loss per share attributable to common stockholders, basic, (in dollars per share) $ (0.62) $ (26.57)
Net loss per share attributable to common stockholders, diluted (in dollars per share) $ (0.62) $ (26.57)
Weighted-average shares of common stock outstanding, basic (in shares) 20,152,872 468,695
Weighted-average common shares outstanding, diluted (in shares) 20,152,872 468,695